Galenea Receives NIH Grant to Develop Flu Drug
Galenea said this week that it has been issued a phase I SBIR grant from the National Institute of Allergy and Infectious Diseases to develop its RNAi-based influenza drug G00101.
Specific details about the grant were not disclosed.
Nastech Presents Preclinical Data on RNAi-based Arthritis Drug
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
